SMMT Latest Headlines

Summit Therapeutics: KOL Backing for Ivonescimab in NSCLC Reinforces Buy Rating and Unchanged $41 Price Target

at www.tipranks.com (Wed, 29-Jul 1:05 PM)

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

at www.tipranks.com (Tue, 28-Jul 10:10 PM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT) and Gossamer Bio (GOSS)

at www.tipranks.com (Tue, 28-Jul 4:30 AM)

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

at www.tipranks.com (Mon, 27-Jul 6:40 AM)

Ivonescimab’s Consistent Survival Benefit Highlights Summit Therapeutics’ Progress—PDUFA Date Set for November 2026

Market Chameleon (Fri, 24-Jul 7:06 AM)

Ivonescimab Plus Chemotherapy Achieves Consistent Survival Benefit for Western and Asian NSCLC Patients: Updated Phase III HARMONi Trial Data

Market Chameleon (Wed, 22-Jul 7:09 AM)

Summit Therapeutics Launches $500 Million Public Offering to Accelerate Ivonescimab Development

Market Chameleon (Wed, 10-Jun 7:05 AM)

Shareholder Investigation Into Summit Therapeutics Inc. Prompts Investors to Consider Recovery Options

Market Chameleon (Mon, 4-May 11:46 AM)

Summit Therapeutics Expands Global Phase III Trials While Cash Reserves Decline Amid Strategic Pipeline Push

Market Chameleon (Fri, 1-May 7:06 AM)